Max Chat
Company Analysis Akebia Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (132.68%) is higher than the sector average (-2.01%).
- The company's current efficiency (ROE=174.03%) is higher than the sector average (ROE=14.17%)
Disadvantages
- Price (3.56 $) is higher than fair price (2.91 $)
- Dividends (0%) are below the sector average (0.5261%).
- Current debt level 21.59% has increased over 5 years from 14.05%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Akebia Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -7% | -20.5% | 3.2% |
| 90 days | 129.7% | -0.7% | 13% |
| 1 year | 132.7% | -2% | 12.8% |
AKBA vs Sector: Akebia Therapeutics, Inc. has outperformed the "Healthcare" sector by 134.69% over the past year.
AKBA vs Market: Akebia Therapeutics, Inc. has outperformed the market by 119.83% over the past year.
Slightly volatile price: AKBA is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: AKBA with weekly volatility of 2.55% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (3.56 $) is higher than the fair price (2.91 $).
Price is higher than fair: The current price (3.56 $) is 18.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (63.23).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (89.86).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-7.93) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (-7.93) is lower than that of the market as a whole (9.35).
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.44) is lower than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (2.44) is lower than that of the market as a whole (10.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-28.13) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-28.13) is lower than that of the market as a whole (50.71).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -16.11% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-16.11%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (174.03%) is higher than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (174.03%) is higher than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-30.02%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-30.02%) is lower than that of the market as a whole (6.88%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5261%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
